The efficacy of the TGF-β×PD-L1 bispecific antibody (BsAb) is not promising clinically. The authors here develop a Y101S, an antibody-drug conjugate targeting TGF-β, PD-L1, and STING, which manifests superior anti-tumor efficacy in preclinical models with the mechanism of enhanced CXCL16 mediated cytotoxic CXCR6+ T cells recruitment.
- Ming Yi
- Tianye Li
- Zhijun Dai
